{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:55:51Z","timestamp":1758477351009},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3267","type":"journal-article","created":{"date-parts":[[2015,2,14]],"date-time":"2015-02-14T22:05:38Z","timestamp":1423951538000},"page":"415-420","source":"Crossref","is-referenced-by-count":2,"title":["Primary Aldosteronism Presenting with an Atypical Aldosterone-renin Ratio in the Acute Phase of Cerebral Hemorrhage"],"prefix":"10.2169","volume":"54","author":[{"given":"Naoka","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Medicine, Beth Israel Medical Center, USA"},{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihisa","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research, Japan"},{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research, Japan"},{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66: 607-618, 2007.","DOI":"10.1111\/j.1365-2265.2007.02775.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 94: 3623-3630, 2009.","DOI":"10.1210\/jc.2009-1399"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Funder JW. The genetic basis of primary aldosteronism. Curr Hypertens Rep 14: 120-124, 2012.","DOI":"10.1007\/s11906-012-0255-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18: 370-373, 1995.","DOI":"10.1007\/BF03347840"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33: 261-266, 1999.","DOI":"10.1016\/S0272-6386(99)70298-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248, 2005.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168: 80-85, 2008.","DOI":"10.1001\/archinternmed.2007.33"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Montori VM, Young WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31: 619-632, 2002.","DOI":"10.1016\/S0889-8529(02)00013-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93: 3266-3281, 2008.","DOI":"10.1210\/jc.2008-0104"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas\/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 90: 871-877, 2005.","DOI":"10.1210\/jc.2004-1627"},{"key":"11","unstructured":"11. Omura M, Nishikawa T. Screening tests and diagnostic examinations of hypertensives for primary aldosteronism. Rinsho Byori (The official Journal of Japanese Society of Laboratory Medicine) 54: 1157-1163, 2006 (in Japanese, Abstract in English)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86: 1083-1090, 2001.","DOI":"10.1210\/jcem.86.3.7287"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 88: 2489-2494, 2003.","DOI":"10.1210\/jc.2002-021476"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 90: 72-78, 2005.","DOI":"10.1210\/jc.2004-1149"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hiraiwa T, Ibata R, Tanimoto K, et al. Acute cerebral hemorrhage normalized plasma renin activity in a patient with primary aldosteronism. Endocrine 36: 383-384, 2009.","DOI":"10.1007\/s12020-009-9272-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hamann GF, Strittmatter M, Hoffmann KH, et al. Pattern of elevation of urine catecholamines in intracerebral haemorrhage. Acta Neurochir (Wien) 132: 42-47, 1995.","DOI":"10.1007\/BF01404846"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gordon RD, K&uuml;chel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Invest 46: 599-605, 1967.","DOI":"10.1172\/JCI105561"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Leow MK, Loh KC, Kiat Kwek T, Ng PY. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common \"pseudophaeochromocytoma\". J Clin Pathol 60: 583-584, 2007.","DOI":"10.1136\/jcp.2006.036640"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Thomas JE, Rooke ED, Kvale WF. The neurologist's experience with pheochromocytoma. A review of 100 cases. JAMA 197: 754-758, 1966.","DOI":"10.1001\/jama.1966.03110100062014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Stowasser M, Gordon RD. Primary aldosteronism--careful investigation is essential and rewarding. Mol Cell Endocrinol 217: 33-39, 2004.","DOI":"10.1016\/j.mce.2003.10.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by Ca<sup>2+<\/sup> channel antagonists. Int J Endocrinol 2012: 519467, 2012.","DOI":"10.1155\/2012\/519467"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension 40: 897-902, 2002.","DOI":"10.1161\/01.HYP.0000038478.59760.41"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 57: 457-465, 2002.","DOI":"10.1046\/j.1365-2265.2002.01613.x"},{"key":"24","unstructured":"24. Seiler L, Rump LC, Schulte-M&ouml;nting J, et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150: 329-337, 2004."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nadler JL, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60: 896-899, 1985.","DOI":"10.1210\/jcem-60-5-896"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yokoyama T, Shimamoto K, Iimura O. Mechanism of inhibition of aldosterone secretion by a Ca<sup>2+<\/sup> channel blocker in patients with essential hypertension and patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi (Folia Endocrinologica Japonica) 71: 1059-1074, 1995 (in Japanese, Abstract in English).","DOI":"10.1507\/endocrine1927.71.7_1059"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Grasko JM, Nguyen HH, Glendenning P. Delayed diagnosis of primary hyperaldosteronism. BMJ 340: 1358-1360, 2010.","DOI":"10.1136\/bmj.c2461"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 36: 499-503, 1992.","DOI":"10.1111\/j.1365-2265.1992.tb02252.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mulatero P, Bertello C, Garrone C, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension 50: e26-e27, 2007.","DOI":"10.1161\/HYPERTENSIONAHA.107.093468"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kem DC, Weinberger MH, Higgins JR, Kramer NJ, Gomez-Sanchez C, Holland OB. Plasma aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension. J Clin Endocrinol Metab 46: 552-560, 1978.","DOI":"10.1210\/jcem-46-4-552"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 25: 514-523, 2012.","DOI":"10.1038\/ajh.2011.245"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T23:21:51Z","timestamp":1566343311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/4\/54_54.3267\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3267","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}